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Abstract
Background:  Subtle functional deficiencies in highly conserved DNA repair or growth regulatory
processes resulting from polymorphic variation may increase genetic susceptibility to breast cancer.
Polymorphisms in DNA repair genes can impact protein function leading to genomic instability facilitated
by growth stimulation and increased cancer risk. Thus, 19 single nucleotide polymorphisms (SNPs) in eight
genes involved in base excision repair (XRCC1, APEX, POLD1), BRCA1 protein interaction (BRIP1, ZNF350,
BRCA2), and growth regulation (TGFß1, IGFBP3) were evaluated.
Methods: Genomic DNA samples were used in Taqman 5'-nuclease assays for most SNPs. Breast cancer
risk to ages 50 and 70 were estimated using the kin-cohort method in which genotypes of relatives are
inferred based on the known genotype of the index subject and Mendelian inheritance patterns. Family
cancer history data was collected from a series of genotyped breast cancer cases (N = 748) identified
within a cohort of female US radiologic technologists. Among 2,430 female first-degree relatives of cases,
190 breast cancers were reported.
Results:  Genotypes associated with increased risk were: XRCC1  R194W (WW and RW vs. RR,
cumulative risk up to age 70, risk ratio (RR) = 2.3; 95% CI 1.3–3.8); XRCC1 R399Q (QQ vs. RR, cumulative
risk up to age 70, RR = 1.9; 1.1–3.9); and BRIP1 (or BACH1) P919S (SS vs. PP, cumulative risk up to age 50,
RR = 6.9; 1.6–29.3). The risk for those heterozygous for BRCA2 N372H and APEX D148E were significantly
lower than risks for homozygotes of either allele, and these were the only two results that remained
significant after adjusting for multiple comparisons. No associations with breast cancer were observed for:
APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFß1 L10P, P25R, and T263I; BRCA2 N289H and T1915M;
BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P.
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Conclusion:  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1
interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous
association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran
counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and
replication of these relationships are warranted.
Background
Subtle functional deficiencies in highly conserved DNA
repair or growth regulatory processes resulting from germ-
line genetic variation have been proposed as possible
mechanisms for increased genetic susceptibility to breast
cancer [1-3], especially since it is estimated that the two
known susceptibility genes BRCA1  and  BRCA2  may
account for less than 4% of all breast cancers [4,5].
Genetic epidemiologic studies suggest that BRCA1/2
account for no more than 20% of the familial risk of
breast cancer, and the residual component is likely to be
due polygenic inheritance of multiple low-penetrance sus-
ceptibility alleles [4-12].
We are conducting genetic studies of breast cancer among
a cohort of U. S. radiologic technologists (USRT), in
which the primary carcinogen under study is occupational
exposure to ionizing radiation. Because the direct and
indirect damaging effects of external radiation include
oxidized bases and DNA single and double strand breaks,
we are investigating 19 candidate variants in eight genes
that are either involved in base excision repair, interact
with the BRCA1 gene, or regulate cell growth. These genes
are also attractive candidates as general breast cancer sus-
ceptibility factors because the repair process is not limited
solely to exogenous radiation damage and includes carci-
nogenic chemicals, dietary constituents, and estrogens. In
addition, growth deregulation is common to many devel-
oping tumors.
In the USRT case-control study, blood samples were col-
lected initially from breast cancer cases during 1999–2001
and are currently being collected from a comparable con-
trol series. The available genotype data of the breast cancer
cases provided an opportunity to perform kin-cohort
analyses [13-15] using the case's family history data. In
kin-cohort analyses, a cohort of relatives of index subjects
is followed for disease occurrence. The genotypes of the
relatives are unknown and are inferred based on the
known genotype of the corresponding index subject (or
proband) and Mendelian inheritance patterns. The kin-
cohort method estimates risks in homozygous or hetero-
zygous carriers and non-carriers of a variant and statisti-
cally accounts for the uncertainty in the indirect genotype
information.
The kin-cohort analysis offers several unique aspects that
distinguish it from the standard case-control analyses we
plan to conduct in the future. First, in a kin-cohort analy-
sis, risk estimates are obtained from the cancer history of
the index cases' family members and thus provide data
independent from the typical case-control analysis [16].
Second, kin-cohort analyses afford an opportunity to eval-
uate potential survival bias when analyzing the breast can-
cer case-control data that may be present given the
prevalence sample in our study. The kin-cohort method is
robust against such survival bias as cancer history among
all family members is analyzed irrespective of the rela-
tive's vital status. Third, the underlying population for the
case-control study is the cohort of radiologic technolo-
gists, who have been exposed to low levels of radiation
from their occupation. The relatives of the radiologic tech-
nologists, however, are unlikely to have experienced occu-
pational radiation exposure. Thus, separate risk estimates
from the kin-cohort analysis and the breast cancer case-
control study will provide information on whether risk
from the genetic variants differs within two populations
that have different background risks from radiation
exposure.
Using the kin-cohort analytic method, we evaluated 19
single nucleotide polymorphism (SNP) variants in the fol-
lowing eight genes: XRCC1, APEX, and POLD1 in the base
excision repair pathway; BRCA2, BRIP1 (or BACH1), and
ZNF350 (or ZBRK1) as BRCA1 interacting proteins; and
the growth factor genes TGFß1 and IGFBP3, and their rela-
tion to breast cancer risk.
Methods
Study population
In 1982, the U. S. National Cancer Institute, in collabora-
tion with the University of Minnesota and the American
Registry of Radiologic Technologists, initiated a study of
cancer incidence and mortality among 146,022 U.S. radi-
ologic technologists who were certified for at least two
years between 1926 and 1982. The primary objectives of
the study are to describe the carcinogenic risks of long-
term, low- to moderate-dose, fractionated occupational
radiation exposures and to determine factors associated
with radiation sensitivity or cancer susceptibility. The cur-
rent median age for cohort members is 53.4 years, and
73% are female. During 1984–1989 and during 1993–
1998, two postal surveys were administered and includedBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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detailed questions related to work history as a radiologic
technologist, lifestyle characteristics, other cancer risk fac-
tors, and health outcomes, including breast cancer.
Approximately 90,000 technologists responded to each
survey. All female technologists reporting a primary breast
cancer that was subsequently confirmed based on medical
records (pathology report, physician's notes, hospital dis-
charge summary or physician correspondence) were eligi-
ble for inclusion if still living. In December 1999, when
biospecimen collection began, there were 1345 living
breast cancer cases with diagnosis years ranging from
1955 to 1998. By the end of December 2001, 748 breast
cancer cases had provided informed consent, a blood
sample, and responded to a telephone interview that col-
lected updated cancer risk factor and family cancer history
information and selected work history data. Another 143
cases could not be located or had an unlisted telephone
number and did not respond to repeated correspondence
inviting participation, 29 were too ill, 238 refused, 21
could not arrange a blood draw or the draw was unsuc-
cessful, and 166 were still in process. This study has been
approved annually by the human subjects review boards
of the National Cancer Institute and the University of
Minnesota.
Birth and death (if applicable) dates and breast cancer
diagnosis dates were obtained for all first-degree female
relatives. Data were evaluated for inconsistencies in age,
reported generational intervals (all mothers had to be at
least 11 years old before the birth of a child), and all
breast cancers must have occurred at an age younger than
current age or age at death. Initially, there were 2497 rela-
tives in the data set and 194 of these relatives were
reported to have breast cancer. For a total of 16 of the
breast cancers reported in female relatives, the age at diag-
nosis was unknown and was imputed using the median
age of breast cancer onset in all the relatives for which age
was known. There were 60 half-sisters and seven relatives
with unknown or un-imputable ages at last observation
who were subsequently excluded. After these exclusions,
2430 relatives were retained in the analyses consisting of
190 with breast cancer and 2240 without.
Genotyping
Approximately 10 nanograms of genomic DNA extracted
from peripheral lymphocytes were used as template in
Taqman 5'-nuclease assays for all SNPs except for TGFß1
P25R, for which a PCR-RFLP assay was used. Taqman
assays were performed using 450 nanomolar primer con-
centrations and 100 nanomolar probe concentrations and
Universal Master Mix (Applied Biosystems). Probes spe-
cific for each SNP were designed with Primer Express soft-
ware (Applied Biosystems) and labeled with either 6-
FAM, TET, or VIC as reporter dyes and either Black Hole
Quencher-1 (IDT, Inc.) or MGB-NFQ (Applied Biosys-
tems) as quenchers. The primer and probe sequences and
PCR conditions for each SNP are available (on request
from JPS at http://lpg.nci.nih.gov/LPG/struewing/pubs).
Most assays were performed in 20 microliter reactions in
96-well trays using a 7700 instrument (Applied Biosys-
tems), but some were performed in 5 microliter reactions
in 384-well trays using a 7900HT instrument (Applied
Biosystems).
Subjects with each of the three possible genotypes (unless
no homozygous variant subjects have ever been identi-
fied) for each SNP were confirmed by sequencing and
included on each genotyping tray. In addition, approxi-
mately 5% of samples (41 samples, distributed as 2 to 7
aliquots of DNA from 8 different anonymous subjects)
were included to monitor quality control (QC), with lab-
oratory personnel blinded as to which were the QC sam-
ples. The genotypes for each of the duplicate QC samples
from a subject matched exactly for all SNPs except one,
and in this case, uncovered a systematic error in coding
the results. This assay was repeated entirely and the QC
samples then matched exactly.
Statistical methods
The analysis was based on a cohort of first degree female
relatives of case probands, i.e., breast cancer patients, who
were followed retrospectively over time for breast cancer
incidence. Although the relatives' genotypes were not
observed, the probability distribution could be inferred
from the observed genotype of the corresponding case
probands and Mendelian inheritance patterns. A marginal
likelihood approach [15] was used to estimate age-specific
cumulative risks associated with different genotypes while
accounting for the uncertainty introduced by using indi-
rect information about the relatives' genotype. Separate
analyses were performed for each locus. For loci with rare
variant frequencies and therefore low power to discern
risk differences, we grouped heterozygote and homozy-
gote variant genotypes together when the prevalence was
less than 10%. For loci with common variants, we first
estimated cumulative risks associated with the three gen-
otypes separately. For two such loci (IGFBP3 -202A>C and
TGFß1 L10P), visual inspection of the age-specific cumu-
lative risk graphs revealed no difference in risk between
homozygotes and heterozygous variant carriers and thus
variant genotypes were combined.
As a summary measure for risk associated with variant
genotypes, we obtained cumulative risk ratios (RR) at ages
50 and 70 with the homozygous wild type genotype con-
sidered the referent category. (Relative risks for breast can-
cer up to any age can be calculated using the kin-cohort
method. We chose to graphically display risks up to age 80
to represent "lifetime" risk. In the tables we chose to pro-
vide risks with confidence intervals (CI) up to ages 50 andBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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70 to depict any differences that could be associated with
earlier vs. later age-at-onset breast cancer [17].) The vari-
ance of the estimated RR was assessed by bootstrap sam-
pling of families. The 95% confidence intervals (CI) for
the estimated RR were based on the 2.5th and 97.5th per-
centiles of the distribution of 1,000 bootstrap replicates of
the RR; the p-values for the estimated RR were two-sided
and also based on 1,000 bootstrap replications. Adjust-
ment for multiple comparisons was performed by either
controlling the probability of at least one falsely rejected
null hypothesis (the so called family-wise error rate [18])
or by controlling the expected proportion of falsely
rejected null hypotheses among all rejected null hypothe-
ses (the so called false discovery rate [19]).
Results
Descriptive characteristics of the radiologic technologists
with breast cancer (index probands) and their first degree
female relatives (with and without breast cancer) are
shown in Table 1. The calendar year of birth and year of
breast cancer diagnosis ranges more widely for relatives
than for probands because relatives spanned three gener-
ations (mother, sister, daughter). Age at first breast cancer
diagnosis was higher among relatives as compared to
probands and reflects the younger ages represented in the
cohort. Nearly equal numbers of breast cancers occurred
in mothers (98) and sisters (85) with seven breast cancers
in daughters.
From among 748 radiologic technologists with breast can-
cer, 99.6% or more of the samples were successfully gen-
otyped (Table 2). Two samples failed repeatedly, leaving
746 consistently genotyped at least 75% of the time. The
genotype frequencies for cases are also shown in Table 2.
Except for BRCA2 N372H and ZBRK1 1845C>T, all distri-
butions were consistent with Hardy Weinberg
Equilibrium.
Many of the variants analyzed showed no appreciable
relationship with breast cancer occurrence (Table 3).
However, several variants were associated with increased
risk of breast cancer, including XRCC1 R194W (WW or
RW vs. RR to age 70; RR = 2.3, 95% CI: 1.3–3.8), XRCC1
R399Q (QQ vs RR to age 50, RR = 3.4; 1.3–9.3), BRIP1
P919S (SS vs PP to age 50; RR = 6.9; 1.6–29.3), and
POLD1 R119H (HH or RH vs. RR to age 70, RR = 1.8; 1.0–
2.9). Risks were significantly reduced for APEX  D148E
heterozygotes (to ages 50 and 70; RR = 0.2; 0.1–0.8 and
Table 1: Descriptive characteristics of breast cancer cases (probands) from the US Radiologic Technologist study and their first degree 
relatives with and without breast cancer.
Characteristic at time of interview 
(1999–2001)
Radiologic technologists with 
breast cancer* (n = 748)
First degree female relatives 
with breast cancer (n = 190)
First degree female relatives without 
breast cancer (N = 2240)
N % N % N %
Year of birth
<1900 0 0.0 19 10.0 165 7.4
1900–29 155 20.7 110 57.9 702 31.3
1930–39 202 27.0 28 14.7 234 10.5
1940–49 276 36.9 20 10.5 271 12.1
1950–59 115 15.4 10 5.3 304 13.6
≥1960+ 0 0.0 3 1.6 564 25.2
Calendar year of breast cancer diagnosis
<1975 43 5.8 56 29.5 NA** ---
1975–79 42 5.6 16 8.4 NA ---
1980–84 98 13.1 20 10.5 NA ---
1985–89 172 23.0 35 18.4 NA ---
1990–94 313 41.8 31 16.3 NA ---
≥1995 80 10.7 32 16.8 NA ---
Age at diagnosis
<40 114 15.2 22 11.6 NA ---
40–49 299 40.0 28 14.7 NA ---
50–59 203 27.1 42 22.1 NA ---
6 0 – 6 9 9 01 2 . 04 92 5 . 8 N A - - -
≥70 42 5.6 49 25.8 NA ---
Relationship to the radiologic technologist (index proband)
Mother NA --- 98 51.6 648 28.9
Sister NA --- 85 44.7 882 39.4
Daughter NA --- 7 3.7 710 31.7
* Includes invasive breast cancer and ductal carcinoma in situ **NA is Not applicableBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
Page 5 of 12
(page number not for citation purposes)
RR = 0.2; 0.1–0.5, respectively) and BRCA2 N372H heter-
ozygotes (to age 70; HR = 0.2; 0.1–0.5) compared to com-
mon homozygotes. When we adjusted the p-values for
multiple comparisons, only the heterozygous associations
of decreased risk up to age 70 in APEX D148E and BRCA2
N372H remained significant at p < 0.001.
Estimates of the cumulative risk by age are graphically dis-
played for each SNP (arranged in alphabetical order) in
Figure 1. The SNPs in Figure 1 are either rare (prevalence
of the homozygous variant was roughly less than 10%) or
little curve separation was seen in the non-parametric
approach, and so heterozygous and homozygous variant
carriers were combined. For SNPs with a higher preva-
lence, estimated cumulative risks are shown in Figure 2 for
each genotype separately. The BRCA2 N372H and BRIP1 -
64 G>A plots show individuals homozygous for the com-
mon allele with risks intermediate between heterozygotes
(lowest breast cancer cumulative risk) and the
homozygous carriers of the rare variant (highest breast
cancer cumulative risk). For APEX  D148E, the risk in
homozygous common or variant carriers is nearly identi-
cal. The XRCC1  R399Q plot shows nearly completely
overlapping risk for the homozygous common allele and
the heterozygotes, but the homozygous variant risk is ele-
vated across the age range. The curves for the BRCA2
N372H and APEX D148E polymorphisms illustrate the
extremely low estimated risk for heterozygous carriers.
Discussion
We found evidence of a differential breast cancer risk asso-
ciated with the variants XRCC1 R194W, XRCC1 R399Q,
BRIP1 P919S, APEX D148E, and BRCA2 N372H using the
kin-cohort analytic method. Multiple forms of DNA
repair are found in mammalian species, of which the base
excision repair pathway is one type involving complex
protein interactions with non-bulky lesions in DNA. Since
XRCC1 is a scaffolding protein integral to base excision
repair [reviewed in [20]], the polymorphic loci in XRCC1
(R194W, R280H and R399Q) have been evaluated for risk
at various cancer sites because their location within the
gene or their conserved status make them ideal candidates
with functional significance more likely [21]. Although
most studies of cancer have found a decreased risk for the
Table 2: Polymorphic variant frequencies among breast cancer cases (probands) from the US Radiologic Technologist Health Study
Gene Polymorphism* Total** 
number
Common homozygote 
frequency
Heterozygote frequency Rare homozygote 
frequency
n%n%n%
Base Excision Repair Genes
XRCC1 R194W(rs1799782) 748 664 88.8 82 11.0 2 0.3
XRCC1 R280H(rs25489) 748 676 90.4 71 9.5 1 0.1
XRCC1 R399Q(rs25478) 748 321 42.9 335 44.8 92 12.3
APEX Q51H(rs1048945) 746 687 92.1 58 7.8 1 0.1
APEX D148E(rs1130409) 745 219 29.4 387 51.9 139 18.7
POLD1 R119H(rs1726801) 748 650 86.9 92 12.3 6 0.8
BRCA1 interacting proteins
BRCA2 N289H(rs2421655) 748 698 93.3 50 6.7 0 0.0
BRCA2 N372H(rs144848)*** 747 405 54.2 274 36.7 68 9.1
BRCA2 T1915I(rs4987717) 748 713 95.3 35 4.7 0 0.0
BRIP1 -64 G>A(rs2048718) 748 211 28.2 370 49.5 167 22.3
BRIP1 P919S(rs4986764) 745 268 36.0 355 47.7 122 16.4
ZBRK1 L66P(rs2278420) 744 535 71.9 190 25.5 19 2.6
ZBRK1 S472P(rs4986771) 748 694 92.8 52 7.0 2 0.3
ZBRK1 R501S(rs2278415) 746 576 77.2 154 20.6 16 2.1
ZBRK1 1845 C>T 
(rs4986770)***
747 640 85.7 107 14.3 0 0.0
Growth factor genes
TGFß1 L10P(rs1982073) 745 263 35.3 357 47.9 125 16.8
TGFß1 P25R(rs1800471) 745 629 84.4 109 14.6 7 0.9
TGFß1 T263I(rs1800472) 748 709 94.8 39 5.2 0 0
IGFΒP3 -202A>C(rs2854744) 746 194 26.0 360 48.3 192 25.7
* Amino acids and their symbols: R: Arginine, W: Tryptophan, H: Histidine, Q: Glutamine, D: Aspartic Acid, E: Glutamic Acid, N: Asparagine, P: 
Proline, S: Serine, L: Leucine, I: Isoleucine, T: Threonine. dbSNP reference sequence number in parentheses. ** Numbers vary because not all the 
cases could be genotyped due to technical issues with the sample. Also some genotyped cases were dropped from kin-cohort analyses because 
telephone interviews had not been completed at the time of blood collection. *** Test for significant deviation from Hardy Weinberg Equilibrium, p 
= 0.05BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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XRCC1 194W allele [reviewed in [22]] including a large
study of breast cancer [23], we found the opposite rela-
tionship. Our results are in agreement with two recent
breast cancer case-control studies that found non-signifi-
cantly elevated 1.6- and 2-fold risks for at least one variant
allele of XRCC1 194 [24,25]. Several studies of female
breast cancer have reported elevated risk associated with
the XRCC1 399Q allele among African Americans [23]
and Koreans [26], but not among Caucasian [23-25,27] or
Chinese women [28]. The mixed findings for the relation-
ship of XRCC1 polymorphisms with breast cancer are dif-
ficult to reconcile, but may simply represent variability
around the null for a non-susceptibility allele. Depending
on the model system chosen, functional testing results
indicate either a reduced DNA repair capacity associated
with the XRCC1 399Gln allele [29], an increase in mitotic
delay among healthy women with a family history of
breast cancer after a γ-ray challenge [30], increased DNA
adduct levels [31], or no difference related to the poly-
morphism in single strand break repair ability or cell sur-
vival in an isogenic background [32]. We evaluated two
polymorphisms in the AP endonuclease APEX (also called
APE1, HAP1, REF1) Q51H and D148E since this multi-
functional endonuclease recognizes and begins the proc-
ess of removing abasic sites in DNA [reviewed in [33]].
Further, the variant form of APEX 148 was functionally
characterized as exhibiting post-irradiation challenge
prolonged mitotic delay [30] and we expected the 148E
allele would be associated with increased risk, but instead
we found heterozygote carriers had significantly decreased
Kin-cohort breast cancer cumulative risk estimates up to age 80 by genotype for less frequent single nucleotide polymorphic  variants among female relatives of probands Figure 1
Kin-cohort breast cancer cumulative risk estimates up to age 80 by genotype for less frequent single nucleotide polymorphic 
variants among female relatives of probands. (Amino acids and their symbols: R: Arginine, W: Tryptophan, H: Histidine, Q: 
Glutamine, D: Aspartic Acid, E: Glutamic Acid, N: Asparagine, P: Proline, S: Serine, L: Leucine, I: Isoleucine, T: Threonine.)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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breast cancer risk. Additional information, both func-
tional and genotypic, is worth pursuing for the APEX 148
variant. POLD1 (polymerase δ) participates in a possibly
redundant sub-pathway within the base excision repair
"long patch" process [reviewed in [33]]. This particular
variant has not been as well characterized in regard to can-
cer risk, compared to other SNPs in base excision repair
genes, but observed RRs in our study were around two-
fold up to ages 50 and 70 such that this SNP deserves fur-
ther study to confirm or refute its role in breast cancer risk.
We evaluated six SNPs recently characterized in the
BRCA1-interacting genes ZNF350 (ZBRK1) and  BRIP1
(BACH1) [34]. Among those, the nonconservative BRIP1
P919S substitution showed a strong association with 4.5-
fold and 6.9-fold (for PS and PP vs. SS, respectively)
increased risks of breast cancer up to age 50. However, the
association was markedly attenuated when observation
was extended to age 70. This could be a chance finding, or,
the variant may be associated predominantly with risk of
pre-menopausal breast cancer. Further evaluation of this
SNP in other study populations will be required.
Two growth factor genes, IGFBP3 and TGFß1, were evalu-
ated because of their roles in controlling cellular growth
and changes associated with malignant progression. Pre-
vious reports suggested an association between the -
202A>C IGFBP3 SNP and risk of pre-menopausal breast
cancer, primarily through its effect on circulating IGFBP3
levels [35] and/or IGF-1 levels [36]. Although we did not
Kin-cohort breast cancer cumulative risk estimates up to age 80 for more frequent single nucleotide polymorphic variants  among female relatives of probands Figure 2
Kin-cohort breast cancer cumulative risk estimates up to age 80 for more frequent single nucleotide polymorphic variants 
among female relatives of probands. (Amino acids and their symbols: D: Aspartic Acid, E: Glutamic acid, R: Arginine, H: Histi-
dine, Q: Glutamine, N: Asparagine, P: Proline, S: Serine.)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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Table 3: Cumulative breast cancer risk ratios to age 50 and to age 70 by genotype among 2430 first degree female relatives of breast 
cancer cases (probands), 190 of whom were reported to have breast cancer
Rare allele frequency To age 50 To age 70
Polymorphism* N** RR 95% CI p-value N** RR 95% CI p-value
Base excision repair genes
XRCC1 R194W 0.06
RR 51 1.0 --- 125 1.0 ---
RW or WW 6 1.4 0.4–4.2 0.408 22 2.3 1.3–3.8 0.004
XRCC1 R280H 0.03
RR 52 1.0 --- 134 1.0 ---
RH or HH 5 0.7 0.0–2.4 0.736 13 1.2 0.5–2.5 0.522
XRCC1 R399Q 0.37
RR 21 1.0 --- 59 1.0 ---
RQ 22 0.7 0.1–2.0 0.444 64 1.1 0.4–1.6 0.636
QQ 14 3.4 1.3–9.3 0.014 24 1.9 1.1–3.9 0.010
APEX Q51H 0.04
QQ 49 1.0 --- 134 1.0 ---
QH or HH 7 3.0 0.5–6.7 0.216 12 1.7 0.7–3.1 0.236
APEX D148E 0.49
DD 20 1.0 --- 49 1.0 ---
DE 27 0.2 0.1–0.8 0.028 65 0.2 0.1–0.5 <0.001
EE 9 0.8 0.2–1.9 0.546 32 1.0 0.6–1.7 0.860
POLD1 R119H 0.06
RR 44 1.0 --- 123 1.0 ---
RH or HH 13 2.5 0.8–5.0 0.106 24 1.8 1.0–2.9 0.058
BRCA1 interacting proteins
BRCA2 N289H 0.03
MM 57 1.0 --- 141 1.0 ---
NH or HH 0 0 --- ---- 6 1.6 0.5–2.9 0.370
BRCA2 N372H 0.32
NN 30 1.0 --- 89 1.0 ---
NH 23 0.4 0.1–1.3 0.140 42 0.2 0.1–0.5 <0.001
HH 4 1.5 0.4–4.4 0.322 16 1.3 0.8–2.4 0.232
BRCA2 T1915M 0.05
TT 53 1.0 --- 139 1.0 ---
TM or MM 4 1.7 0.0–4.0 0.664 8 2.1 0.6–3.6 0.215
BRIP1 -64 G>A 0.46
GG 17 1.0 --- 42 1.0 ---
GA 24 0.4 0.1–1.2 0.126 70 0.7 0.2–1.2 0.112
AA 16 1.5 0.5–4.3 0.424 35 1.6 0.8–2.8 0.218
BRIP1 P919S 0.43
PP 10 1.0 --- 52 1.0 ---
PS 34 4.5 0.8–12.2 0.096 69 0.6 0.3–1.2 0.134
SS 12 6.9 1.6–29.3 0.018 25 1.3 0.8–2.8 0.220
ZBRK1 L66P 0.15
LL 43 1.0 --- 108 1.0 ---
LP or PP 14 0.9 0.3–2.0 0.712 38 1.2 0.7–1.9 0.304
ZBRK1 S472P 0.12
SS 55 1.0 --- 137 1.0 ---
SP or PP 2 0.8 0.0–2.2 0.614 10 1.6 0.6–2.9 0.312
ZBRK1 R501S 0.12
RR 46 1.0 --- 116 1.0 ---
RS or SS 11 0.8 0.2–1.8 0.534 31 1.2 0.7–2.1 0.434
ZBRK1 1845 C>T 0.06
CC 45 1.0 --- 121 1.0 ---
CT or TT 12 2.2 0.5–4.3 0.218 25 1.6 0.8–2.8 0.162
Growth factor genes
TGFß1 L10P 0.38
LL 25 1.0 --- 54 1.0 ---
LP or PP 31 0.5 0.2–1.2 0.148 92 0.8 0.5–1.5 0.536
TGFß1 P25R 0.10BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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directly assess the relationship between the IGFBP3-
202A>C variant and circulating IGFBP3 and IGF-1 levels,
we did not observe an association between this SNP (as an
indicator of IGF-1 levels) and breast cancer risk in our
study. Three SNPs in the TGFß1 gene (L10P, P25R, and
T263I) have previously been described [37], with the
L10P variant showing some association with increased
risk of breast cancer [38,39]. Our data do not support an
association between these TGFß1 SNPs and breast cancer
risk in this cohort.
Of all the SNPs evaluated, BRCA2 N372H had shown the
most consistent relationship to breast cancer in previous
studies: in both a European study [40] and an Australian
study [41], HH homozygotes had significantly elevated
odds ratios for breast cancer of 1.3 to 1.5 compared to NN
homozygotes, and in a study of ovarian cancer from the
UK and Australia [42], risk was similarly elevated (OR =
1.4) for HH homozygotes. In all three of these studies,
there was no evidence of increased (or decreased) risk
among heterozygotes, with ORs of 1.01 to 1.03, compared
to NN homozygotes. In our study, HH homozygotes had
a slightly increased RR of 1.5 (95% CI, 0.4–4.4) and 1.3
(95% CI, 0.8 – 2.4) over NN homozygotes up to ages 50
and 70, respectively. Unlike the previous studies, hetero-
zygotes had a significantly reduced breast cancer risk com-
pared to NN homozygotes. The minor allele frequency
was somewhat higher in our study (0.32) of cases, versus
approximately 0.28 in the UK\Australian study [42]. In
the initial study [40], it was noted that the SNP in female
controls was not in Hardy-Weinberg equilibrium (HWE),
with an excess of heterozygotes and a deficit of both
homozygotes. In our case series, the SNP was not in HWE,
with 23 fewer heterozygotes than expected and more than
20% over the expected numbers of HH homozygotes
under HWE; this is the trend one might have expected if
the H allele increases risk. In addition, the 9.1% HH gen-
otype frequency in our breast cancer cases was very similar
to that observed in the Australian breast cancer study
(9.2%) [41]. Whether the breast cancer risk is lower in het-
erozygotes, as is clearly evident in the risk curves from our
analyses, or whether the inconsistent findings are still due
to chance (even after multiple comparisons adjustment)
are not known and will require further study in case-con-
trol analyses in this cohort or other large epidemiologic
studies.
Because the striking heterozygous advantage in BRCA2
N372H and APEX D148E were unexpected and difficult to
interpret biologically, we performed analyses stratified by
type of relative (mother, sister). We discovered that, in
general, the kin-cohort model for three genotype catego-
ries is not identifiable when restricted to mothers of the
index cases because the matrix of Mendelian genotype
probabilities for relatives conditional on the genotype
and type of relative of the index case is rank deficient. This
meant that calculations restricted to mothers could not be
performed, but we could determine the relationship
between individual SNPs and breast cancer among sisters.
Therefore, we relied on the analysis restricted to sisters to
corroborate patterns observed for all relatives combined.
For sisters only, the analyses revealed the same patterns as
shown in Figure 2, which were based on all female rela-
tives, except for APEX D148E, where the results for sisters
only showed similar risks for homozygous common and
heterozygous genotypes and an increased risk for
homozygous variant genotypes (data not shown). Due to
the biological inconsistency of the results for APEX D148E
and because of the differences between analyses based on
sisters only and all relatives, we suggest caution in inter-
preting this result, despite the statistical significance. For
BRCA2 N372H, results for sisters only were very similar to
results for all relatives combined, lending credence to our
observations, despite the difficult interpretation.
There are several study limitations. Fifty-six per cent of the
women eligible donated a blood sample before the
arbitrary genotyping cut-off date (December 31, 2001).
PP 48 1.0 --- 126 1.0 ---
PR or RR 8 1.0 0.1–3.1 0.952 20 1.2 0.6–2.1 0.554
TGFß1 T263I 0.04
TT 54 1.0 --- 138 1.0 ---
TI or II 3 2.1 0.0–4.9 0.492 9 1.7 0.6–3.1 0.312
IGFBP3 -202 A>C 0.53***
AA 11 1.0 --- 36 1.0 ---
AC or CC 45 1.0 0.3–3.5 0.848 110 0.7 0.4–1.3 0.228
* Amino acids and their symbols: R: Arginine, W: Tryptophan, H: Histidine, Q: Glutamine, D: Aspartic Acid, E: Glutamic Acid, N: Asparagine, P: 
Proline, S: Serine, L: Leucine, I: Isoleucine, T: Threonine. ** Numbers represent those first degree female relatives who had breast cancer up to age 
50 or 70 by the genotype of the case (index proband). The numbers are not the probabilistic assignment of the kin-cohort calculation to a specific 
genotype. *** Represents the frequency of the C allele, although not technically "rare".
Table 3: Cumulative breast cancer risk ratios to age 50 and to age 70 by genotype among 2430 first degree female relatives of breast 
cancer cases (probands), 190 of whom were reported to have breast cancer (Continued)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
Page 10 of 12
(page number not for citation purposes)
Reasons for eligible women not providing a blood sample
were that they could not be located, refused, or were too
ill. The distribution of demographic and known breast
cancer risk factors such as education, age at menarche, age
at first live birth, age at breast cancer diagnosis, and year
of birth were similar for participants and non-partici-
pants. Unsurprisingly, women over age 80 in 1999 were
less likely to provide a blood sample (63% did not pro-
vide a blood sample compared to 48% for those under age
80). Regarding employment characteristics, more women
who began to work in the 1950s tended to donate a sam-
ple (57%) compared to women who began work after
1970 (43%). Interestingly, women who reported a first
degree relative with breast cancer were less inclined to
donate a sample (44% vs. 53% of those with no family
breast cancer history). However, for selection bias to have
caused spurious associations, the differential
participation would also need to be related to genotype, a
generally improbable scenario. Another limitation was
that the kin-cohort method is less powerful for common
genotypes, such that discrimination in risk is reduced
because the "at risk" allele assignment among relatives
becomes less precise with increasing prevalence. Statistical
power, in the presence of null results, is important to
report, but these calculations for the kin-cohort method
are computationally difficult. Since the statistical power to
detect a two-fold increased or decreased effect in a case-
control study with 190 breast cancer cases and 2240 con-
trols for the homozygous variant genotype or the com-
bined homozygous variant and heterozygous genotypes
(for polymorphisms with rare homozygous variant geno-
type) ranges from 0.30 to 0.99 (assuming a = 0.05, two-
sided test, and the SNP frequency varies between 0.01 to
0.25), we conclude the statistical power of our kin-cohort
study was even less because the genotypes of the relatives
were not known with certainty and multiple genotypes
were evaluated. Breast cancers among first degree family
members were not independently confirmed by medical
records, however we considered that breast cancer was
likely to be accurately reported in family members of
breast cancer cases [43] and possibly even more so
because the cases are trained to work in the medical field
as radiologic technologists. It is not possible to adjust for
breast cancer risk factors among family members,
although all of the relatives, by definition, have a first-
degree relative with breast cancer. Relative risk estimates
from the kin-cohort analyses should not be affected, how-
ever absolute risk estimates could be inflated above the
true values.
There were a large number of comparisons evaluated (n =
46), such that one or more relationships reported here
could be due solely to chance. Of all the hypotheses tested
in Table 3, only those corresponding to the two p-values
< 0.001 (BRCA2 N372H heterozygous vs. homozygous
common and APEX D148E heterozygous vs. homozygous
common) can be rejected while controlling the family-
wise error rate, i.e. the probability of a least one false
positive at 0.05 [18] or while controlling the false discov-
ery rate, i.e. the expected proportion of false positives
among the positives at 0.05 [19]. It has to be noted that
the hypotheses tested may not be independent. For exam-
ple, SNPs in the same gene may be in linkage disequilib-
rium with each other and the risk to age 50 and risk to age
70 are presumably not independent. In this situation, our
correction for multiple comparisons is likely overly con-
servative. However, the associations that we found signif-
icant at 0.05, but not 0.001, are certainly suggestive and
serve as a means of hypothesis generation. Even though
the kin-cohort design allows for the evaluation of gene-
gene interactions [17], we did not perform such an analy-
sis because of its very low statistical power and because of
a lack of strong prior biologic hypotheses about the joint
effect of SNPs in the genes studied.
The study and the kin-cohort method have several
strengths and advantages. The strengths are that risks are
determined by the breast cancer experience in relatives,
who are included whether living or deceased, reducing
concerns of selection bias from recruiting prevalent cases.
The study uses information on risk from a group outside
the parent study, essentially providing a rationale for later
testing using other designs and increases confidence if
similar associations are observed in the upcoming case-
control study. In addition, the breast cancer risks among
female relatives are independent of specific occupational
exposures (in this study, medical radiation exposure from
work as a radiologic technologist) that were the reason for
the cohort assembly and follow-up. A very important fea-
ture is that a control series is not required, such that this
method could easily be implemented among hospital-
based cases. Once the genotypes are known for the index
case series, risks for other common cancer outcomes (such
as prostate, lung, or colon cancer) can readily be com-
puted using family cancer history information collected at
the time of blood sampling. Thus, the kin-cohort study
provides additional independent supplemental data to an
existing (or in progress) case-control study [16].
In summary, differences in breast cancer risk were associ-
ated with XRCC1 R194W, XRCC1 R399Q, BRIP1 P919S,
APEX D148E and BRCA2 N372H, and were suggestive for
several others. Although HH homozygotes for the BRCA2
N372H SNP had approximately 30% greater odds of
breast cancer compared to NN homozygotes, as had been
consistently observed in two previous studies of breast
cancer [40,41], this association was weak, and we
observed a significantly decreased risk among heterozy-
gotes, a relationship that had not been suggested previ-
ously. We express caution in the interpretation of theBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/9
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decreased breast cancer risk observed for APEX  D148E
heterozygotes. It is possible that one or more of the
XRCC1  R194W,  XRCC1  R399Q,  BRIP1  P919S variants
could eventually be regarded as low-penetrance risk alle-
les for breast cancer, but after adjustment for multiple
comparisons, none remained statistically significant. Ulti-
mately, results from this kin-cohort analysis can be com-
bined with findings from the standard case-control study
for a more consistent interpretation of the risk associated
with common genetic variants.
Conclusions
Some variants in genes within the base-excision repair
pathway (XRCC1) and BRCA1 interacting proteins
(BRIP1) may play a role as low penetrance breast cancer
risk alleles. Previous association studies of increased
breast cancer risk for BRCA2  N372H and decreased
function for APEX D148E variants were not in agreement
with our findings of decreased risks. Due to the many
comparisons, cautious interpretation and replication of
these relationships are warranted.
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